Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model.
about
PDGFRB promotes liver metastasis formation of mesenchymal-like colorectal tumor cellsEarly endostatin treatment inhibits metastatic seeding of murine colorectal cancer cells in the liver and their adhesion to endothelial cells.Angiostatin generating capacity and anti-tumour effects of D-penicillamine and plasminogen activators.[Efficacy and safety of rh-endostatin combined with chemotherapy versus chemotherapy alone for advanced NSCLC: a meta-analysis review].Recent developments in antiangiogenic therapy.Synergistic antitumor efficacy by combining adriamycin with recombinant human endostatin in an osteosarcoma model.Angiogenesis inhibitors found within the haemostasis pathway.Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer.Downregulation of tumstatin expression by overexpression of ornithine decarboxylaseA Multi-Mitochondrial Anticancer Agent that Selectively Kills Cancer Cells and Overcomes Drug Resistance.Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice.Perinecrotic hypoxia contributes to ischemia/reperfusion-accelerated outgrowth of colorectal micrometastases.The synergistic effect of recombinant human endostatin (YH-16) combined with oxaliplatin on human colorectal carcinoma.ABC-Transporter Expression Does Not Correlate with Response to Irinotecan in Patients with Metastatic Colorectal Cancer.Role of Angiogenesis in Chronic Radiation Proctitis: New Evidence Favoring Inhibition of Angiogenesis Ex Vivo.
P2860
Q30536377-11DDE264-7EF4-42B7-BAC5-BC58F6CEC103Q33211600-08AE33BD-8297-41A5-B3D0-95FB27A3A0FEQ33245745-AA3900F5-DD4D-4877-AC17-38B6FBBF4867Q33395300-54140FE0-7FFC-4015-B602-4F3F70664498Q35040867-EF51D3D7-D73E-4466-AE88-A202A95B3495Q36126820-522E744E-91C1-410D-B86A-D995044A18EBQ36166483-997A3900-E88E-4C7E-A951-D9057D964745Q36187034-0F774192-E905-4187-B373-526014E4B8FCQ37288527-63539122-9C0E-4CB0-82AD-0A8FA440FB64Q38720819-164F6529-8BE7-4861-8569-8BD6F86BEC6FQ39015610-0DAF37C3-68C3-4DD2-BE36-7949C7D7AE4AQ40153030-A0402873-EAC4-4B1E-BB0F-595B2EAE1BCEQ43127546-F283DFC1-DAD6-4BC5-9C5F-B99045563294Q43206841-AB8C1D03-51D3-47C3-8EA6-BC3403035B98Q50100724-55222FDA-6194-4345-8F45-774ABCD877C0
P2860
Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Enhanced antitumour efficacy b ...... n in a liver metastasis model.
@en
Enhanced antitumour efficacy b ...... n in a liver metastasis model.
@nl
type
label
Enhanced antitumour efficacy b ...... n in a liver metastasis model.
@en
Enhanced antitumour efficacy b ...... n in a liver metastasis model.
@nl
prefLabel
Enhanced antitumour efficacy b ...... n in a liver metastasis model.
@en
Enhanced antitumour efficacy b ...... n in a liver metastasis model.
@nl
P2093
P2860
P1476
Enhanced antitumour efficacy b ...... n in a liver metastasis model.
@en
P2093
Borel Rinkes IH
Gebbink MF
te Velde EA
van Gorp JM
P2860
P304
P356
10.1046/J.1365-2168.2002.02183.X
P407
P577
2002-10-01T00:00:00Z